PSY4-4 Clinical oncology research environment in Malaysia: now and future

Abstract

The Malaysian government is committed to improve clinical research infrastructure. More than 7 years after Clinical Research Malaysia (CRM) formation, we have more than 150 Clinical Research Sites and 850 clinical research investigators registered for multiple discipline of medicine. The top 10 common cancers in Malaysia includes Breast, Colorectal, Lung, Lymphoma, Nasopharynx, Leukemia, Prostate, Cervical, Liver and Ovarian cancer. Every tear Malaysia conducted 40 new Oncology clinical research sponsored by multinational companies. Majority are in Clinical Trial Phase 2 and 3. In 2017, CRM launch Phase 1 Realisation Program to produce First in Human (FIH) Phase 1 centers. 2 years later the first FIH center was accredited for Phase FIH Clinical Research. The Oncology disease prevalence is indifferent with the developed nation couple with multiple variety of population, Malaysia is ideal for clinical research destination. In addition, the conduct of Clinical Research is governed by Good Clinical Practice with ISO 9001:2015 accredited Standard Operating Procedure. The conducive environments mean clinical research are delivered according to the speed, reliability and quality. The recent reported recruitment rate at 83% has prepared the clinical research sites in facing COVID-19 pandemic where we will describe the recovery of clinical research recruitment is accelerated. The speaker will share data on how the research environment in Malaysia transformed creating conducive environment for oncology clinical research. Consequently, achieving 2 out of 3 National Key Economic Area Key Performance Index, ahead by almost 3 years with new jobs created and more number industry sponsored research conducted in the country.